20. Cost-Effectiveness of Implementing 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) for Adults Aged ≥19 Years with Underlying Conditions

BACKGROUND: In June 2019, the U.S. Advisory Committee on Immunization Practices changed the recommendation for routine PCV13 use in immunocompetent adults aged ≥65, including those with certain chronic medical conditions (CMC); PCV13 is now recommended based on shared clinical decision-making. Adult...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Kobayashi, Miwako, Stoecker, Charles, Xing, Wei, Cho, Bo-Hyun, Pilishvili, Tamara
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Poster Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776097/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.065
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky